CORRESP Filing
Design Therapeutics, Inc.
Date: May 14, 2025 · CIK: 0001807120 · Accession: 0001193125-25-119753
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287043
Letter
Re: Design Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-287043) Filed: May 7, 2025 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Design Therapeutics, Inc. (the “ Company ”) hereby requests that the Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement to become effective on May 16, 2025 at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as the Company or its counsel may request by telephone to the staff of the Commission. The Company hereby authorizes each of Kenneth J. Rollins and Asa M. Henin of Cooley LLP, counsel to the Company, to make such a request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Kenneth J. Rollins of Cooley LLP at (858) 550-6136 or Asa M. Henin of Cooley LLP at (858) 550-6104. [Signature Page Follows]
DESIGN THERAPEUTICS, INC. 6005 Hidden Valley Road, Suite 110 Carlsbad, California 92011 May 14, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Dickerson
Sincerely,
D ESIGN T HERAPEUTICS , I NC .
Show Raw Text
CORRESP 1 filename1.htm CORRESP DESIGN THERAPEUTICS, INC. 6005 Hidden Valley Road, Suite 110 Carlsbad, California 92011 May 14, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Dickerson Re: Design Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-287043) Filed: May 7, 2025 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Design Therapeutics, Inc. (the “ Company ”) hereby requests that the Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement to become effective on May 16, 2025 at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as the Company or its counsel may request by telephone to the staff of the Commission. The Company hereby authorizes each of Kenneth J. Rollins and Asa M. Henin of Cooley LLP, counsel to the Company, to make such a request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Kenneth J. Rollins of Cooley LLP at (858) 550-6136 or Asa M. Henin of Cooley LLP at (858) 550-6104. [Signature Page Follows] Sincerely, D ESIGN T HERAPEUTICS , I NC . By: /s/ Pratik Shah, Ph.D. Pratik Shah, Ph.D. President, Chief Executive Officer and Chairperson cc: Mustapha Parekh, Design Therapeutics, Inc. Kenneth J. Rollins, Cooley LLP Asa M. Henin, Cooley LLP